Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Current Assets: 2020-2025

Historic Current Assets for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $21.4 million.

  • Insight Molecular Diagnostics' Current Assets rose 346.25% to $21.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 346.25%. This contributed to the annual value of $11.8 million for FY2024, which is 9.92% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Current Assets stood at $21.4 million for Q3 2025, which was down 20.32% from $26.8 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Current Assets ranged from a high of $62.8 million in Q1 2021 and a low of $4.8 million during Q3 2024.
  • For the 3-year period, Insight Molecular Diagnostics' Current Assets averaged around $16.6 million, with its median value being $14.3 million (2023).
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Current Assets slumped by 71.67% in 2024, and later spiked by 454.90% in 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Current Assets (Quarterly) stood at $39.1 million in 2021, then tumbled by 34.76% to $25.5 million in 2022, then plummeted by 58.11% to $10.7 million in 2023, then increased by 9.92% to $11.8 million in 2024, then spiked by 346.25% to $21.4 million in 2025.
  • Its last three reported values are $21.4 million in Q3 2025, $26.8 million for Q2 2025, and $36.3 million during Q1 2025.